CANF · Can-Fite BioPharma Ltd.
Market Cap
$4.67M
Shares
2.14M
Volume · Oct 2
27.42K
Avg daily vol (3M)
411.72K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.18
Open$2.20
Day$2.18–2.22
52W close$2.16–12.40
Avg vol 30d738K
Short int59K · 2.8% float · 1.0d
Short vol19%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-39.9%
Year over year
Operating margin
-2,456.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+127.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.8%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−23%
below
RSI (14)
34
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−25%
trailing
YTD return
−45%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-43% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.77% of float · ▼ -4.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
8 holders — near 3-yr low, contrarian setup
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−40%
Y/Y
EPS growth
+45%
Y/Y
Free cash flow
$-9.0M
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
34
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-43% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.77% of float · ▼ -4.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
8 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $12
vs 200-day avg -37%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CANF
this stock
Can-Fite BioPharma Ltd.
|
$4.67M | — | -39.9% | — | 2.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CANF | +1.0% | -7.2% | -25.3% | -0.8% | -45.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +1.2% | -6.7% | -37.5% | -1.7% | -58.3% |